55 research outputs found
Пам'яті Миколи Чумаченка
14 жовтня на 87-ому році життя відійшов у вічність видатний учений-економіст, доктор економічних наук, академік Національної академії наук України, заслужений діяч науки і техніки України, лауреат Державної премії України в галузі науки і техніки, лауреат премій АН УРСР ім. О.Г. Шліхтера та НАН України ім. М.І. Тугана-Барановського, почесний директор Інституту економіки промисловості НАН України, ветеран Великої Вітчизняної війни, почесний громадянин міста Донецька голова редакційної колегії журналу Схід з економіки Микола Григорович Чумаченко
253: The effect of statins on the risk of first non-fatal myocardial infarction: A population-based observational study using the PGRx information system
BackgroundDespite demonstrated positive effects in a number of clinical trials, the evidence is lacking as to the impact of statins on the risk of first myocardial infarction (MI) in real life settings.ObjectivesTo assess the impact of real life statin utilization on the risk of first non-fatal MIMethodsCase-control methodology using the pharmacoepidemiological information system PGRx. Data on comorbidities, risk factors and medications were obtained from medical records and patient telephone interviews. General practices (n=371) and cardiology centres (n=60) across France were employed in the study. Cases were patients with the first MI ≤ 1 month before the date of recruitment (n=2238). Controls were patients seen by a general practitioner (GP) with no restriction as to the reasons of consultation (n=2238), matched to MI cases on gender, age, frequency of visits to a doctor, date of recruitment and personal history of non-cardiovascular chronic disease. Statin exposure was defined as any utilisation in the two-year prior to date of MI in cases or recruitment date in controls. Adjusted odds ratios (OR) of the risk of first MI was estimated by multiple conditional logistic regression models. Comparative effectiveness and propensity to use of individual statin molecules were assessed.ResultsThe use of statins was associated with a lower MI risk (adjusted OR 0.67 [95% CI 0.56 - 0.79] for current use (within 2 months before the index date) and 0.73 [0.62 0.86] for any use within 24 months). Among individual statins, rosuvastatin was associated with the lowest MI risk (adjusted OR 0.49 [0.35 - 0.68] for any use in 24 months preceding the index date) followed by simvastatin (0.62 [0.46 - 0.84]).ConclusionsIn this first major population-based observational study we reproduced the results observed in recent meta-analyses accounting for real life compliance and population variability. The results could be of interest and applicable to other industrialised countries as the observed risk reduction was constant across MI risk levels
Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices
Benchmarking clinical management of spinal and non-spinal disorders using quality of life: results from the EPI3-LASER survey in primary care
Concerns have been raised regarding sub-optimal utilization of analgesics and psychotropic drugs in the treatment of patients with chronic musculoskeletal disorders (MSDs) and their associated co-morbidities. The objective of this study was to describe drug prescriptions for the management of spinal and non-spinal MSDs contrasted against a standardized measure of quality of life. A representative population sample of 1,756 MSDs patients [38.5% with spinal disorder (SD) and 61.5% with non-spinal MSDs (NS-MSD)] was drawn from the EPI3-LASER survey of 825 general practitioners (GPs) in France. Physicians recorded their diagnoses and prescriptions on that day. Patients provided information on socio-demographics, lifestyle and quality of life using the Short Form 12 (SF-12) questionnaire. Chronicity of MSDs was defined as more than 12 weeks duration of the current episode. Chronic SD and NS-MSD patients were prescribed less analgesics and non-steroidal anti-inflammatory drugs than their non-chronic counterpart [odds ratios (OR) and 95% confidence intervals (CI), respectively: 0.4, 0.2–0.7 and 0.5, 0.3–0.6]. They also had more anxio-depressive co-morbidities reported by their physicians (SD: 16.1 vs.7.4%; NS-MSD: 21.6 vs. 9.5%) who prescribed more antidepressants and anxiolytics with a difference that was statistically significant only for spinal disorder patients (OR, 95% CI: 2.0, 1.1–3.6). Psychotropic drugs were more often prescribed in patients in the lower quartile of SF-12 mental score and prescriptions of analgesics in the lower quartile of SF-12 physical score (P < 0.001). In conclusion, anxiety and depressive disorders were commonly reported by GPs among chronic MSD patients. Their prescriptions of psychotropic and analgesic drugs were consistent with patients’ self-rated mental and physical health
Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study
Evaluation and application of a new systematic case-referents method in pharmacoepidemiology
L’objectif de ce travail est de présenter et évaluer une nouvelle méthode, PGRx,systématique cas-référents en pharmaco-épidémiologie avec son application à l’étudede l’infarctus du myocarde (IDM). Elle se distingue par la collecte systématique etcontinue de cas d’événements dans des centres spécialisés et d’un pool de référenceen médecine générale dont sont tirés les témoins appariés aux cas. L’évaluation durisque d’IDM associé au diclofénac (OR 1.5) et celle du bénéfice associé aux statines(OR 0.75) montrent des résultats similaires à ceux publiés (respectivement OR 1.4 etOR 0.74). Nous montrons que les référents sont un échantillon représentatif de lapopulation française en termes de motif de consultation et valide en termesd’évaluation de facteurs de risque. La concordance entre la mesure de l’exposition parla déclaration du patient et par les prescriptions médicales est excellente pour lesmédicaments cardiovasculaires (95%). Notre travail sur une série d’études montre quela collecte systématique de cas et d’un pool de référence, selon la méthode PGRx, estfaisable, reproductible et valide en termes de résultats et d’indicateurs de qualité.The objective of this work is to present and assess PGRx, a new systematic case-referentsmethod in pharmacoepidemiology and its application on the study of themyocardial infarction (MI). The originality of PGRx is the systematic and on-goingcollect of cases of events in a network of specialized centres and of a pool of referentsin general practice (GP), from which controls are selected by matching to the cases.The assessment of the risk of MI associated with diclofenac (OR 1.5) and of thebenefit on MI associated with statins (OR 0.75) displays similar results than theliterature (respectively OR 1.4 and OR 0.74).We show that the pool of referents is arepresentative sample of the French population in terms of reasons of consulting a GPand valid in terms of risk factors’assessment. Agreement between the measure ofexposure from patients’ self-report and from physician’s report of their prescriptionsis excellent on cardiovascular drugs (95%). Our work, through several studies, showsthat the systematic collect of cases and of a reference pool by the PGRx method isfeasible, reproducible and valid in terms of results and quality indicators
Evaluation et application d'une nouvelle méthode systématique cas-référents en pharmaco-épidémiologie. Etudes dans l'infarctus du myocarde.
L objectif de ce travail est de présenter et évaluer une nouvelle méthode, PGRx,systématique cas-référents en pharmaco-épidémiologie avec son application à l étudede l infarctus du myocarde (IDM). Elle se distingue par la collecte systématique etcontinue de cas d événements dans des centres spécialisés et d un pool de référenceen médecine générale dont sont tirés les témoins appariés aux cas. L évaluation durisque d IDM associé au diclofénac (OR 1.5) et celle du bénéfice associé aux statines(OR 0.75) montrent des résultats similaires à ceux publiés (respectivement OR 1.4 etOR 0.74). Nous montrons que les référents sont un échantillon représentatif de lapopulation française en termes de motif de consultation et valide en termesd évaluation de facteurs de risque. La concordance entre la mesure de l exposition parla déclaration du patient et par les prescriptions médicales est excellente pour lesmédicaments cardiovasculaires (95%). Notre travail sur une série d études montre quela collecte systématique de cas et d un pool de référence, selon la méthode PGRx, estfaisable, reproductible et valide en termes de résultats et d indicateurs de qualité.The objective of this work is to present and assess PGRx, a new systematic case-referentsmethod in pharmacoepidemiology and its application on the study of themyocardial infarction (MI). The originality of PGRx is the systematic and on-goingcollect of cases of events in a network of specialized centres and of a pool of referentsin general practice (GP), from which controls are selected by matching to the cases.The assessment of the risk of MI associated with diclofenac (OR 1.5) and of thebenefit on MI associated with statins (OR 0.75) displays similar results than theliterature (respectively OR 1.4 and OR 0.74).We show that the pool of referents is arepresentative sample of the French population in terms of reasons of consulting a GPand valid in terms of risk factors assessment. Agreement between the measure ofexposure from patients self-report and from physician s report of their prescriptionsis excellent on cardiovascular drugs (95%). Our work, through several studies, showsthat the systematic collect of cases and of a reference pool by the PGRx method isfeasible, reproducible and valid in terms of results and quality indicators.TOURS-Bibl.électronique (372610011) / SudocSudocFranceF
Etude des prescriptions de médicaments en dépit d'une contre-indication en pédiatrie
TOURS-BU Sciences Pharmacie (372612104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
- …